[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![BiopharmIQ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::811036897883492352.png) BiopharmIQ by Amp [@BiopharmIQ](/creator/twitter/BiopharmIQ) on x 25.7K followers
Created: 2025-07-17 21:33:21 UTC

$GSK
📣 FDA’s ODAC votes against belantamab mafodotin combos
in R/R multiple myeloma

❌ 5–3 vote against BVd (with bortezomib) 
👎👎👎👎👎 vs. 👍👍👍

❌ 7–1 vote against BPd (with pomalidomide) 
👎👎👎👎👎👎👎 vs. 👍

⚠️ Reason: High ocular toxicity & poor tolerability
despite PFS gains in DREAMM-7/8

FDA questioned dosage selection 
& real-world relevance of trial data
Committee urged exploration of lower, more tolerable doses

📉 A tough call: 
Strong efficacy, but stronger toxicity concerns


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945960037979242732/c:line.svg)

**Related Topics**
[rates](/topic/rates)
[realworld](/topic/realworld)
[$gsk](/topic/$gsk)
[gsk plc](/topic/gsk-plc)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/BiopharmIQ/status/1945960037979242732)